| 1. |
Should corticosteroids be used in RA? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 2-2
&NA;,
Preview
|
PDF (869KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 2. |
Understanding attitudes about biotechnology drugs |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 3-4
Mark Greener,
Preview
|
PDF (1559KB)
|
|
摘要:
The fruits of biotechnological research are having a growing impact on the pharmaceutical market. However, a recent study found that doctors don't apply the same decision-making process to biotechnological products as they use for conventional pharmaceuticals. The study suggests that understanding these differences could help purchasers and prescribers work together to optimise outcomes when using biotechnology drugs. For example, formulary management strategies for biotechnological products should place greater emphasis on clinical and humanistic outcomes than cost.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 3. |
IDSA publishes guidelines for community-acquired pneumonia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 4-4
&NA;,
Preview
|
PDF (772KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 4. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 5-5
&NA;,
Preview
|
PDF (766KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 5. |
Switch from immediate-release to extended-release glipizide and save |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 6-6
&NA;,
Preview
|
PDF (803KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 6. |
Squaring the drug development circle |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 7-8
Mark Greener,
Preview
|
PDF (1593KB)
|
|
摘要:
Governments, in the industrialised world at least, struggle to square the drug development circle. The growing pressure on healthcare budgets means purchasers seek to control drug costs. However, the pharmaceutical industry is one of the most successful industrial sectors and governments want to maintain a supportive research and development (R&D) environment. To resolve this tension, policy-makers need accurate estimates of the cost of pharmaceutical R&D.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 7. |
Tibolone improves QOL in menopausal symptoms |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 8-8
&NA;,
Preview
|
PDF (803KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 8. |
Melagatran is promising in acute deep vein thrombosis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 9-9
&NA;,
Preview
|
PDF (741KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 10-10
&NA;,
Preview
|
PDF (755KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 10. |
Excitement over oral GP IIb/IIIa receptor antagonists dies down |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1182,
1999,
Page 11-12
Tracey Earl,
Preview
|
PDF (1605KB)
|
|
摘要:
The future for oral glycoprotein (GP) IIb/IIIa receptor antagonists looks uncertain following the release of disappointing results from the first large trials of these drugs at the 48th Annual Scientific Session of the American College of Cardiology [New Orleans, US; March 1999]. GP IIb/IIIa receptor antagonists are considered to be the most potent antiplatelet drugs available to date. However, these agents are currently only available in IV form, and underlying cardiac events are said to continue after termination of treatment. Therefore, development of orally active GP IIb/IIIa receptor antagonists would allow administration for a longer period of time, making them more suitable for long-term prevention of coronary thrombosis.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
首页
